Workers from Google, Microsoft, Amazon, and Meta are paying $75,000 to be taller, a surgeon told GQ.
The Las Vegas surgeon can lengthen patients' legs via a painful months-long process.
He breaks the thigh bones and inserts nails that are extended every day for three months.
A Las Vegas cosmetic surgeon who specializes in leg-lengthening procedures that can extend people's height by 3 to 6 inches told GQ magazine that many of his patients are tech workers.
Kevin Debiparshad founded LimbplastX Institute in 2016, and the clinic's business has boomed during the pandemic, he told GQ.
Here's how it works: The doctor breaks the patients' femurs, or thigh bones, and inserts metal nails into them that can be adjusted. The nails are extended a tiny bit every day for three months with a magnetic remote control, GQ reported.
It can take months to slowly lengthen the bones and for the legs to heal. One software engineer told GQ he spent the first three months after his surgery alone in his apartment and ordered delivery food during that time to go from 5-foot-6 to 5-foot-9.
The procedure costs between $70,000 and $150,000, depending on whether the patient wants to grow 3, 4, 5, or 6 inches, GQ said.
The common denominator of Debiparshad's client base is that they're wealthy, but they vary by profession: GQ reported that he'd treated CEOs, actors, and finance employees. And a bevy of high-earning tech workers — mostly men but some women — have come to him for the procedure.
"I joke that I could open a tech company," Debiparshad told GQ. "I got, like, 20 software engineers doing this procedure right now who are here in Vegas. There was a girl yesterday from PayPal. I've got patients from Google, Amazon, Facebook, Microsoft. I've had multiple patients from Microsoft."
The surgeon said he didn't recommend the procedure for athletes since it could decrease their ability, and many of the patients GQ spoke to said they didn't tell people they had the procedure done.
The stigma around plastic surgery for men has begun to fall away in recent years. Cosmetic procedures performed on men went up 325% from 1997 to 2015, according to the American Society for Aesthetic Plastic Surgery.
And within Silicon Valley, plastic surgery has increasingly become a way for male tech workers to reach their physical goals in recent years.
The Washington Post reported in January 2020 that men were turning to Botox, fillers, laser treatments, and techniques meant to stimulate collagen in an effort to get ahead in their careers.
Are you a tech worker who has undergone leg-lengthening surgery? Contact the author from a non-work email at kcanales@insider.com
Read the original article on Business Insider
Talk about setting a precedent...View Entire Post ›
Stéphane Bancel discusses the company’s latest Covid shot and prospects for using mRNA in seasonal flu vaccines and personalized treatments for cancer
Intellia said Friday it knocked out the gene responsible for a rare and deadly swelling disorder. But CRISPR stocks sank.
Omeros Corp (NASDAQ: OMER) reported results from the narsoplimab arm of the I-SPY COVID Trial, sponsored by Quantum Leap Healthcare Collaborative (QLHC). Narsoplimab showed the largest reduction in mortality risk to date across all drugs reported from the I-SPY COVID Trial. The company said that in approximately half of the patients died in the narsoplimab group, and narsoplimab was not given or was prematurely stopped, with those patients dying 9 to 35 days later. Omeros adds that despite narso
Investors have lost patience with the slow-paced clinical trials of genetic therapies, and some are using the upbeat news to exit Intellia and peers.
A San Francisco-based immunology company that wants to help eradicate infectious disease globally has expanded its footprint in St. Louis, opening a new $41 million office within the Cortex innovation district. It says the new facility will be critical to advancing research to treat several infectious diseases, including Covid-19.
Regeneron (REGN) and its partner Alnylam announce promising data from its ongoing phase I study evaluating ALN-HSD in healthy adults and NASH patients.
Gilead Sciences Inc (NASDAQ: GILD) announced updates to the World Health Organization's (WHO) Therapeutics and COVID-19: living guideline, which now conditionally recommends Veklury (remdesivir) for severe COVID-19. WHO continues to conditionally recommend Veklury in those with non-severe COVID-19 at the highest risk of hospitalization. The WHO conditional recommendation is mainly driven by the final results of the WHO-sponsored SOLIDARITY study, which showed a statistically significant 17% lowe
These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q4 2022.
In that spirit, let's examine two healthcare stocks that seem to have the tools to provide solid returns over the long term: Eli Lilly (NYSE: LLY) and Teladoc Health (NYSE: TDOC). Eli Lilly seems to excel in both areas. Take one of the company's most recent approvals: Mounjaro, a therapy used to control blood glucose levels in patients with type 2 diabetes.
A labor shortage at a pharmaceutical company along with increased demand left Adderall on back-order at many pharmacies across the country.
Based on positive top-line data from phase III on its pentavalent meningococcal vaccine, Pfizer (PFE) intends to submit a regulatory application to the FDA seeking approval by year-end.
Intellia Therapeutics said two of its experimental Crispr treatments produced positive results in early-stage trials.
J&J (JNJ) announces a new $5 billion stock buyback plan. CHMP recommends authorizing Pfizer's (PFE) Omicron BA.4 and BA.5 boosters in Europe.
The following two healthcare stocks look like great buys for investors seeking to collect both above-average income and increase wealth. The good news for cancer patients is that Merck's (NYSE: MRK) cancer drug called Keytruda is approved in the U.S. to treat 19 different forms of the disease. Looking out over the long term, Merck's pipeline is just as strong as its existing products.
Gilead's (GILD) Veklury is now recommended by the WHO for use in both non-severe COVID-19 patients at the highest risk of hospitalization and those with severe COVID-19.
Eloxx Pharmaceuticals' (ELOX) phase II combination study evaluating pipeline candidate ELX-02 in cystic fibrosis fails to achieve statistical significance in efficacy endpoints.
"If we are forcing millions of people into this world, we as a society — whether you are right, whether you are left, whether you are 'pro-life' or not — it doesn't matter. You will all suffer the consequences of a crowded, broken political, healthcare, and education system."View Entire Post ›
OpSens Inc. ("OpSens" or the "Company") (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, today announced that it has received 510(k) regulatory clearance from the U.S. Food & Drug Administration ("FDA") for the SavvyWire™ ("SavvyWire"), its new guidewire for transcatheter aortic valve replacement procedures, or TAVR.
By M. Marin NASDAQ:ABVC READ THE FULL ABVC RESEARCH REPORT Moving lead assets and earlier stage candidates forward … ABVC BioPharma (NASDAQ:ABVC), a biopharma and medical device company developing therapies for a range of conditions focused on oncology/hematology, central nervous system (CNS) and ophthalmology, provided an update in a letter to shareholders this week. With a broad pipeline of